p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma

Cancer Gene Therapy

Volumn 9, Issue 10, 2002, Pages 807-812

  Sauter, Edward R ^a,b   Takemoto, Richelle ^a   Litwin, Samuel ^c   Herlyn, Meenhard ^a  

^a WISTAR INSTITUTE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Antisense; Cyclin D1; Malignant melanoma; Treatment

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; BETA GALACTOSIDASE; CYCLIN D1; PROTEIN P53; THYMIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; GENE THERAPY; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR VOLUME; WILD TYPE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BETA-GALACTOSIDASE; CYCLIN D1; DEFECTIVE VIRUSES; DNA, ANTISENSE; DRUG THERAPY, COMBINATION; GENE THERAPY; HUMANS; INJECTIONS, INTRALESIONAL; LAC OPERON; MELANOMA, EXPERIMENTAL; MICE; MICE, SCID; SKIN NEOPLASMS; SURVIVAL RATE; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE; ANIMALIA;

EID: 0036789552     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700492     Document Type: Article

References (35)

1. ACS. Cancer Facts and Figures 2002. Atlanta: American Cancer Society, 2002.
2. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA. 1991;88:10124-10128.
3. Lee JY, Dong SM, Shin MS, et al. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. Biochem Biophys Res Commun. 1997;237:667-672.
4. Weiss J, Heine M, Arden KC, et al. Mutation and expression of TP53 in malignant melanomas. Recent Results Cancer Res. 1995;139:137-154.
5. Hartmann A, Blaszyk H, Cunningham JS, et al. Overexpression and mutations of p53 in metastatic malignant melanomas. Int J Cancer. 1996;67:313-317.
6. Ley RD, Applegate LA, Padilla RS, et al. Ultraviolet radiation-induced malignant melanoma in Monodelphia domestica. Photochem Photobiol. 1989;50:1-5.
7. Romerdahl CA, Stephens LC, Bucana C, et al. The role of ultraviolet radiation in the induction of melanocytic skin tumors in inbred mice. Cancer Commun. 1989;1:209-216.
8. Berking C, Takemoto R, Satyamoorthy K, et al. Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin. Am J Pathol. 2001;158:943-953.
9. Helin K, Harlow E. The retinoblastoma protein as a transcriptional repressor. Trends Cell Biol. 1992;3:43-46.
10. Deng C, Zhang P, Harper JW, et al. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 1995;82:675-684.
11. Evdokiou A, Raggatt LJ, Atkins GJ, el al. Calcitonin receptor-mediated growth suppression of HEK-293 cells is accompanied by induction of p21WAF1/CIP1 and G2/M arrest [In Process Citation]. Mol Endocrinol. 1999;13:1738-1750.
12. Zhan Q, Antinore MJ, Wang XW, et al. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene. 1999;18:2892-2900.
13. Hinds PW, Dowdy SF, Eaton EN, et al. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA. 1994;91: 709-713.
14. Matsushime HD, Quelle E, Shurtleff SA, et al. D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol. 1994;14:2066-2076.
15. Rieber MS, Rieber M. Suppression of cyclin D1 but not cdk4 or cyclin A with induction of melanoma terminal differentiation. Biochem Biophys Res Commun. 1995;216:422-427.
16. Bartkova J, Lukas J, Guldberg P, et al. The p16-cyclin D1/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 1996;56:5475-5483.
17. Satyamoorthy K, Chehab NH, Waterman MJ, et al. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ. 2000;11:467-474.
18. Sauter ER, Nesbit M, Litwin S, et al. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res. 1999;59:4876-4881.
19. Sauter ER, Yeo UC, van Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002;3200-3206.
20. Jenq W, Wu SJ, Kefalides NA. Expression of the alpha 2- subunit of laminin correlates with increased cell adhesion and metastatic propensity. Differentiation. 1994;58:29-36.
21. Herlyn D, Iliopoulos D, Jensen PJ, et al. In vitro properties of human melanoma cells metastatic in nude mice. Cancer Res. 1990;50:2296-2302.
22. Iliopoulos D, Ernst C, Steplewski Z, et al. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst. 1989;81:440-444.
23. Graham FL, Smiley J, Russell WC, et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59-74.
24. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75: 817-825.
25. Wilkinson GWG, Akrigg A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res. 1992;20:2233-2239.
26. Ranheim TS, Shisler J, Horton TM, et al. Characterization of mutants within the gene for the adenovirus E3 q4.7 - kilodalton protein which prevents cytolysis by tumor necrosis factor. J Virol. 1993;67:2159-2167.
27. Hung W-C, Huang J-S, Chuang L-Y. Antisense oligodeoxynucleotides targeted against different regions of cyclin D1 mRNA may exert different inhibitory effects on cell growth and gene expression. Biochem Biophys Res Commun. 1996; 220:719-723.
28. Schrump DS, Chen A, Consoli U. Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther. 1996;3: 131-135.
29. Kommann M, Arber N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest. 1998; 101:344-352.
30. Driscoll B, Wu L, Buckley S, et al. Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth. Am J Physiol. 1997;273:L941-L949.
31. Arber N, Doki Y, Han E-H, et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 1997;57:1569-1574.
32. Li Z, Rakkar A, Katayose Y, et al. Efficacy of multiple administrations of a recombinant adenovirus expressing wildtype p53 in an immune-competent mouse tumor model. Gene Ther. 1998;5:605-613.
33. Powell SN, DeFrank JS, Connell P, et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 1995;55:1643-1648.
34. St John LS, Sauter ER, Herlyn M, et al. Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53. Cancer Gene Ther. 2000;7:749-756.
35. Putzer BM, Bramson JL, Addison CL, et al. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum Gene Ther. 1998;9:707-718.